Navigating the ADC Development Pathway
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges.
In this webinar, experts discuss approaches for target validation and strategies to address ADC bioanalytical and DMPK challenges. Further discussion focuses on approaches for nonclinical safety evaluation, underscoring the need to assess both intact ADCs and novel payloads in relevant animal models. This webinar offers a comprehensive perspective on strategies crucial to accelerating research and development of antibody-drug conjugates.
Related Content
Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...
VIEW RESOURCEAntibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...
VIEW RESOURCE